MX2013003060A - Terapia de combinacion para tratar infeccion por hcv. - Google Patents

Terapia de combinacion para tratar infeccion por hcv.

Info

Publication number
MX2013003060A
MX2013003060A MX2013003060A MX2013003060A MX2013003060A MX 2013003060 A MX2013003060 A MX 2013003060A MX 2013003060 A MX2013003060 A MX 2013003060A MX 2013003060 A MX2013003060 A MX 2013003060A MX 2013003060 A MX2013003060 A MX 2013003060A
Authority
MX
Mexico
Prior art keywords
hcv infection
treating hcv
combination therapy
compound
pharmaceutically acceptable
Prior art date
Application number
MX2013003060A
Other languages
English (en)
Inventor
George Kukolj
Carla Haefner
Wulf Boecher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013003060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013003060A publication Critical patent/MX2013003060A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a combinaciones terapéuticas que comprenden (a) Compuesto (1) o una sal farmacéuticamente aceptable del mismo, como se describe en la presente memoria, (b) Compuesto (2) o una sal farmacéuticamente aceptable del mismo, como se describe en la presente memoria y opcionalmente (c) ribavirina y métodos para usar tales combinaciones terapéuticas para el tratamiento de la infección por HCV o mejorar uno o más síntomas de la misma en un paciente.
MX2013003060A 2010-09-30 2011-09-23 Terapia de combinacion para tratar infeccion por hcv. MX2013003060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38825310P 2010-09-30 2010-09-30
PCT/EP2011/066567 WO2012041771A1 (en) 2010-09-30 2011-09-23 Combination therapy for treating hcv infection

Publications (1)

Publication Number Publication Date
MX2013003060A true MX2013003060A (es) 2013-05-30

Family

ID=44735903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003060A MX2013003060A (es) 2010-09-30 2011-09-23 Terapia de combinacion para tratar infeccion por hcv.

Country Status (20)

Country Link
US (1) US20120135949A1 (es)
EP (1) EP2621495A1 (es)
JP (1) JP2013540112A (es)
KR (1) KR20130116245A (es)
CN (1) CN103228278A (es)
AP (1) AP2013006734A0 (es)
AU (1) AU2011310761A1 (es)
BR (1) BR112013007423A2 (es)
CA (1) CA2813093A1 (es)
CL (1) CL2013000670A1 (es)
CO (1) CO6700843A2 (es)
EA (1) EA201300421A1 (es)
EC (1) ECSP13012551A (es)
MA (1) MA34547B1 (es)
MX (1) MX2013003060A (es)
PE (1) PE20131397A1 (es)
SG (1) SG188238A1 (es)
TW (1) TW201306839A (es)
WO (1) WO2012041771A1 (es)
ZA (1) ZA201300992B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159245B (zh) * 2008-09-17 2013-07-24 贝林格尔.英格海姆国际有限公司 Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
DE202012012956U1 (de) * 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
UY34401A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013147749A1 (en) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7027A (en) * 1850-01-15 Circulak
US10006A (en) * 1853-09-06 Improvement in printer s ink
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2004094452A2 (en) * 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
EA009295B1 (ru) * 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
KR20060054410A (ko) * 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 플라비비리다에에 대한 2고리 이미다졸 유도체
SI1718608T1 (sl) * 2004-02-20 2013-11-29 Boehringer Ingelheim International Gmbh Inhibitorji virusne polimeraze
WO2005116054A1 (en) * 2004-05-25 2005-12-08 Boehringer Ingelheim International, Gmbh Process for preparing acyclic hcv protease inhibitors
KR20070112165A (ko) 2005-02-11 2007-11-22 베링거 인겔하임 인터내셔날 게엠베하 2,3-이치환된 인돌의 제조방법
EP1910337A2 (en) * 2005-06-24 2008-04-16 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
WO2007019397A2 (en) * 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
WO2009021121A2 (en) * 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
JP5520301B2 (ja) 2008-09-16 2014-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 強力なｈｃｖ阻害剤である２−チアゾリル−４−キノリニル−オキシ誘導体の結晶形態
CN102159245B (zh) 2008-09-17 2013-07-24 贝林格尔.英格海姆国际有限公司 Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
SG171771A1 (en) 2008-11-21 2011-07-28 Boehringer Ingelheim Int Pharmaceutical composition of a potent hcv inhibitor for oral administration
CA2767692C (en) 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor

Also Published As

Publication number Publication date
SG188238A1 (en) 2013-04-30
TW201306839A (zh) 2013-02-16
CN103228278A (zh) 2013-07-31
MA34547B1 (fr) 2013-09-02
CA2813093A1 (en) 2012-04-05
EP2621495A1 (en) 2013-08-07
BR112013007423A2 (pt) 2016-07-12
CL2013000670A1 (es) 2013-08-09
ECSP13012551A (es) 2013-06-28
PE20131397A1 (es) 2014-01-04
KR20130116245A (ko) 2013-10-23
EA201300421A1 (ru) 2013-08-30
AP2013006734A0 (en) 2013-02-28
US20120135949A1 (en) 2012-05-31
WO2012041771A1 (en) 2012-04-05
CO6700843A2 (es) 2013-06-28
AU2011310761A1 (en) 2013-02-21
ZA201300992B (en) 2014-07-30
JP2013540112A (ja) 2013-10-31

Similar Documents

Publication Publication Date Title
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
PH12018502489A1 (en) Antiviral therapy
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
HRP20180237T4 (hr) Metode za liječenje hcv-a
MX2014003180A (es) Metodos para tratar vhc.
TN2011000200A1 (en) Combination therapy with peptide epoxyketones
MY152824A (en) Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
EA201200890A1 (ru) Комбинированная терапия hcv
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
EA201490199A8 (ru) Терапевтические способы
MX356704B (es) Combinación.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
TW201129361A (en) Methods for treating pain
MX2012015102A (es) Agentes terapeuticos 976.
TN2013000134A1 (en) Combination therapy for treating hcv infection
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
WO2010138889A8 (en) Peptides for the treatment of hcv infections
UA103907C2 (ru) Терапевтический режим лечения гепатита, который включает пег-интерферон, рибавирин и vx-950
TH139548A (th) การบำบัดรักษาแบบผสมผสาน สำหรับการรักษาการติดเชื้อ hcv

Legal Events

Date Code Title Description
FA Abandonment or withdrawal